SELLAS Life Sciences Group, Inc.
SLS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001390478
No open-market purchases or sales by SELLAS Life Sciences Group, Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding SELLAS Life Sciences Group, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 33 | 31 | −2 |
| Shares | 5.41M | 6.22M | +809.7K (+15.0%) |
| Value | $6.76M | $6.47M | −$290.5K (−4.3%) |
New holders (6)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 127,821 | $132.9K | 0.00% |
| Goldman Sachs Group Inc | 15,683 | $16.3K | 0.00% |
| Jane Street Group, LLC | 12,304 | $12.8K | 0.00% |
| Prosperity Financial Group, Inc. | 11,500 | $12.0K | 0.01% |
| SBI Securities Co., Ltd. | 5,464 | $5.68K | 0.00% |
| R Squared Ltd | 2,197 | $2.29K | 0.00% |
Sold out (8)
Institutions that held SELLAS Life Sciences Group, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Diametric Capital, LP | 160,194 | $200.2K |
| Renaissance Technologies LLC | 92,937 | $116.2K |
| Prelude Capital Management, LLC | 58,338 | $72.9K |
| Millennium Management LLC | 46,335 | $57.9K |
| Two Sigma Investments, LP | 16,591 | $20.7K |
| Calton & Associates, Inc. | 14,000 | $17.5K |
| JPMorgan Chase & Co | 5,789 | $7.24K |
| CWM, LLC | 10 | $0 |